<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2758619/" ref="ordinalpos=727&amp;ncbi_uid=2463562&amp;link_uid=PMC2758619" image-link="/pmc/articles/PMC2758619/figure/F4/" class="imagepopup">Figure 4. <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">pathway</span> activation in mammary tumors.  From: NEDD9 promotes oncogenic <span class="highlight" style="background-color:">signaling</span> in mammary tumor development. </a></div><br /><div class="p4l_captionBody"><b>A</b>. Signaling interactions of Nedd9 relevant to mammary tumor development. <b>B, C</b>. Western analysis demonstrates expression and activation levels of the indicated proteins in primary tumor lysates, and quantification of relative difference in activation between Nedd9-/- and Nedd9+/+ mice. <b>D</b>. Degree of pathway activation as a correlate of initial tumor appearance (see data in Figures <b>1A, 1C</b>). The statistical trend is highly significant for time of initial detection of tumors (p&lt;0.001 for all proteins evaluated).</div></div>